Gyrus Capital holds €700M final close on Continuation Fund

GENEVA, Switzerland – 30 April 2025 – Gyrus Capital, a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors, has held a final close on a €700m single-asset continuation vehicle for Essential Pharma (“Essential”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas.

Initially formed in December 2024 to support the recapitalisation of Essential Pharma, alongside a €300m strategic financing facility with Sixth Street, the continuation vehicle will also enable Essential to deploy additional capital to build on its diversified portfolio across established and rare disease medicines through its successful acquisition and development strategy, supporting Essential’s mission to ensure access to essential medicines for patients across new and existing markets. Since her appointment in 2023, CEO Emma Johnson has driven the company’s expansion into rare diseases, with the addition of marketed product Colobreathe® and Hu14.18, an immunotherapy in late-stage clinical development for the treatment of high-risk neuroblastoma.

With over €100m raised in incremental commitments in Q1-25, the continuation vehicle closed slightly above the Hard Cap of €700m. The continuation vehicle held an initial close in December and was led by AlpInvest and supported by a significant participation from StepStone Group and other high-quality new and existing investors, as well as a meaningful reinvestment from both Gyrus and management. The second close was comprised of returning investors and a select group of new investors.

Dr Robert Watson, Managing Partner at Gyrus Capital, said: “We are delighted to announce the incremental support for Essential Pharma which will provide additional firepower for Essential as it delivers on its M&A strategy and accelerates its expansion into rare diseases.”

About Gyrus Capital
Gyrus Capital is a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus invests in businesses that address the structural needs of society and the environment and are positioned for long-term sustainable growth. The firm focuses on complex transactions, particularly corporate carve-outs in the €50 million to €500 million range. A renowned group of experienced partners and industry experts supports Gyrus’s active investment and value-creation approach, working closely with entrepreneurs and managers. To learn more, please visit www.gyruscapital.com


About Essential Pharma
Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to clinically differentiated, niche, branded medicines across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease. The group’s growth strategy is centred on portfolio optimisation and a targeted M&A approach to acquire commercial and late-clinical stage assets in the four therapeutic areas of focus. It is a trusted partner to multiple pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous supply to patients. For more information, please visit www.essentialpharmagroup.com